SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
hep26640-sup-0001-suppinfo.doc60KSupporting Information
hep26640-sup-0002-suppfig1.doc1259KSupporting Information Figure 1. Sorafenib did not significantly affect the phosphatase activity of SHP-2 in HCC cells and purified SHP-2 proteins. (A) The activity of SHP-2. HCC cells (PLC5, Hep3B, SK-Hep1, and Huh7) were exposed to sorafenib at 10 μM for 24 h. The SHP-2 activity was relative to non-treatment cells. (B) Dose-dependent SHP-2 activity. PLC5 cells were incubated with sorafenib at the indicated dose for 24 h. Sorafenib caused 30∼35% increase in SHP-2 activity at relative high dose. (C) Sorafenib could not directly increase SHP-2 activity in vitro. Recombinant wild-type SHP-2 protein was co-incubated with sorafenib at the indicated dose for 30 min in vitro. Columns, mean; bars, SD (n ≧ 6).
hep26640-sup-0003-suppfig2.doc1259KSupporting Information Figure 2. SC-43, SC-40, and regorafenib did not significantly affect the phosphatase activity of SHP-2 in HCC cells and in purified SHP-2 proteins. (A) The activity of SHP-2. PLC5 and HepG2 were exposed to SC-43 at the indicate dose for 24 h. SC-43 (1 and 5 μM) increased 30∼35% SHP-2 activity in both PLC5 and HepG2 cells. (B) PLC5 and HepG2 were exposed to SC-40 at the indicate dose for 24 h. (C) PLC5 and HepG2 were exposed to regorafenib at the indicate dose for 24 h. Regorafenib caused a dose-dependent decrease of SHP-2 activity in HepG2. (D) SC-43, 40 and regorafenib could not directly increase SHP-2 activity in vitro. Purified SHP-2 proteins were co-incubated with SC-43, 40, or regorafenib at 1 μM for 30 min in vitro. Columns, mean; bars, SD (n ≧ 6).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.